ECSP21082527A - Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares - Google Patents
Anticuerpos anti-sema3a y sus usos para tratar enfermedades ocularesInfo
- Publication number
- ECSP21082527A ECSP21082527A ECSENADI202182527A ECDI202182527A ECSP21082527A EC SP21082527 A ECSP21082527 A EC SP21082527A EC SENADI202182527 A ECSENADI202182527 A EC SENADI202182527A EC DI202182527 A ECDI202182527 A EC DI202182527A EC SP21082527 A ECSP21082527 A EC SP21082527A
- Authority
- EC
- Ecuador
- Prior art keywords
- eye diseases
- sema3a
- antibodies
- treat eye
- sema3a antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a anticuerpos y fragmentos de estos que actúan sobre semaforina 3A (Sema3A). Más específicamente, se divulgan anticuerpos anti-Sema3A y métodos de uso para el tratamiento de varias enfermedades o trastornos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19173454 | 2019-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP21082527A true ECSP21082527A (es) | 2021-12-30 |
Family
ID=66476463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202182527A ECSP21082527A (es) | 2019-05-09 | 2021-11-18 | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
Country Status (23)
Country | Link |
---|---|
US (2) | US11267880B2 (es) |
EP (1) | EP3966239A1 (es) |
JP (2) | JP7314310B2 (es) |
KR (1) | KR20220007128A (es) |
CN (1) | CN113795509A (es) |
AR (1) | AR122266A1 (es) |
AU (1) | AU2020267874A1 (es) |
BR (1) | BR112021019854A2 (es) |
CA (1) | CA3137377A1 (es) |
CL (1) | CL2021002795A1 (es) |
CO (1) | CO2021014768A2 (es) |
CR (1) | CR20210559A (es) |
DO (1) | DOP2021000226A (es) |
EA (1) | EA202193038A1 (es) |
EC (1) | ECSP21082527A (es) |
IL (1) | IL287758A (es) |
JO (1) | JOP20210300A1 (es) |
MA (1) | MA55872A (es) |
MX (1) | MX2021013671A (es) |
PE (1) | PE20220287A1 (es) |
SG (1) | SG11202110842QA (es) |
TW (1) | TWI836069B (es) |
WO (1) | WO2020225400A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR122266A1 (es) | 2019-05-09 | 2022-08-31 | Boehringer Ingelheim Int | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
US20220127344A1 (en) * | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
EP4314047A1 (en) * | 2021-03-30 | 2024-02-07 | Bayer Aktiengesellschaft | Anti-sema3a antibodies and uses thereof |
CN116790610A (zh) * | 2023-05-18 | 2023-09-22 | 四川大学 | 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
WO2011055550A1 (ja) * | 2009-11-05 | 2011-05-12 | 国立大学法人大阪大学 | 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法 |
WO2013005603A1 (ja) * | 2011-07-01 | 2013-01-10 | 公立大学法人横浜市立大学 | 結膜におけるアレルギー性炎症の予防及び/又は治療剤 |
US9879075B2 (en) | 2013-02-06 | 2018-01-30 | Yokohama City University and Chiome Bioscience Inc. | Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same |
AU2014221144B2 (en) * | 2013-02-21 | 2018-03-22 | Rsem, Limited Partnership | Inhibition of Sema3A in the prevention and treatment of ocular hyperpermeability |
ES2865488T3 (es) * | 2014-09-05 | 2021-10-15 | Rsem Lp | Composiciones y métodos para el tratamiento y la prevención de la inflamación |
KR101854529B1 (ko) * | 2015-10-27 | 2018-05-04 | (주) 팬젠 | 인간 및 마우스 Sema3A에 교차결합하는 항체 및 그의 용도 |
AU2016346595B2 (en) | 2015-10-27 | 2019-11-14 | Pangen Biotech Inc. | Antibody to be cross-linked to human and mouse Sema3A, and use thereof |
US10604571B2 (en) | 2015-10-27 | 2020-03-31 | Samsung Life Public Welfare Foundation | Antibody to human and mouse SEMA3A and use thereof |
AR122266A1 (es) | 2019-05-09 | 2022-08-31 | Boehringer Ingelheim Int | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
-
2020
- 2020-05-08 AR ARP200101337A patent/AR122266A1/es unknown
- 2020-05-08 CN CN202080034499.1A patent/CN113795509A/zh active Pending
- 2020-05-08 WO PCT/EP2020/062802 patent/WO2020225400A1/en active Application Filing
- 2020-05-08 PE PE2021001846A patent/PE20220287A1/es unknown
- 2020-05-08 EP EP20723153.1A patent/EP3966239A1/en active Pending
- 2020-05-08 JO JOP/2021/0300A patent/JOP20210300A1/ar unknown
- 2020-05-08 BR BR112021019854A patent/BR112021019854A2/pt unknown
- 2020-05-08 JP JP2021565942A patent/JP7314310B2/ja active Active
- 2020-05-08 SG SG11202110842QA patent/SG11202110842QA/en unknown
- 2020-05-08 US US16/869,618 patent/US11267880B2/en active Active
- 2020-05-08 MX MX2021013671A patent/MX2021013671A/es unknown
- 2020-05-08 CR CR20210559A patent/CR20210559A/es unknown
- 2020-05-08 EA EA202193038A patent/EA202193038A1/ru unknown
- 2020-05-08 TW TW109115394A patent/TWI836069B/zh active
- 2020-05-08 KR KR1020217040292A patent/KR20220007128A/ko unknown
- 2020-05-08 CA CA3137377A patent/CA3137377A1/en active Pending
- 2020-05-08 AU AU2020267874A patent/AU2020267874A1/en active Pending
- 2020-05-08 MA MA055872A patent/MA55872A/fr unknown
-
2021
- 2021-10-25 CL CL2021002795A patent/CL2021002795A1/es unknown
- 2021-11-01 DO DO2021000226A patent/DOP2021000226A/es unknown
- 2021-11-01 IL IL287758A patent/IL287758A/en unknown
- 2021-11-02 CO CONC2021/0014768A patent/CO2021014768A2/es unknown
- 2021-11-18 EC ECSENADI202182527A patent/ECSP21082527A/es unknown
-
2022
- 2022-01-25 US US17/583,245 patent/US20220144929A1/en not_active Abandoned
-
2023
- 2023-07-12 JP JP2023114243A patent/JP2023130473A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022531698A (ja) | 2022-07-08 |
TW202108621A (zh) | 2021-03-01 |
AR122266A1 (es) | 2022-08-31 |
PE20220287A1 (es) | 2022-02-25 |
US20200385446A1 (en) | 2020-12-10 |
CO2021014768A2 (es) | 2021-11-19 |
BR112021019854A2 (pt) | 2022-02-15 |
JP7314310B2 (ja) | 2023-07-25 |
AU2020267874A1 (en) | 2021-10-28 |
TWI836069B (zh) | 2024-03-21 |
DOP2021000226A (es) | 2021-12-15 |
SG11202110842QA (en) | 2021-10-28 |
JOP20210300A1 (ar) | 2023-01-30 |
CR20210559A (es) | 2021-12-23 |
CL2021002795A1 (es) | 2022-08-05 |
EA202193038A1 (ru) | 2022-03-30 |
KR20220007128A (ko) | 2022-01-18 |
CN113795509A (zh) | 2021-12-14 |
MX2021013671A (es) | 2021-12-10 |
US20220144929A1 (en) | 2022-05-12 |
MA55872A (fr) | 2022-03-16 |
WO2020225400A1 (en) | 2020-11-12 |
IL287758A (en) | 2022-01-01 |
EP3966239A1 (en) | 2022-03-16 |
JP2023130473A (ja) | 2023-09-20 |
CA3137377A1 (en) | 2020-11-12 |
US11267880B2 (en) | 2022-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP21082527A (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares | |
CL2020000483A1 (es) | Nuevos usos de derivados de piperidinil–indol. | |
CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
CL2019002566A1 (es) | Anticuerpos anti-phf-tau y usos de estos. | |
CO2018010504A2 (es) | Inhibidores del enlace proteína-proteína de wdr5 | |
PE20210488A1 (es) | Anticuerpos especificos para gucy2c y sus usos | |
CL2021000163A1 (es) | Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139) | |
CO2020009402A2 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
UY37594A (es) | Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer | |
UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
CO2018003852A2 (es) | Proteínas de unión a antigeno que activan el receptor de leptina | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
CO2019009787A2 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos | |
CO2022002001A2 (es) | Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr | |
CR20180529A (es) | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada | |
CO2018004569A2 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
ECSP19008417A (es) | Anticuerpos con inmunogenicidad baja y usos de estos | |
CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
CL2021001615A1 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
CO2024007361A2 (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
CO2023000557A2 (es) | Anticuerpos y métodos para tratar enfermedades asociadas a claudina | |
CO2021007444A2 (es) | Anticuerpos antiperiostina y usos de estos | |
CO2022003324A2 (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
ECSP22020678A (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares |